Skip to main content

11.10.2019 | Health Services Research and Global Oncology

Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers

verfasst von: Douglas S. Swords, MD, MS, Sean J. Mulvihill, MD, Benjamin S. Brooke, MD, PhD, Matthew A. Firpo, PhD, Courtney L. Scaife, MD

Erschienen in: Annals of Surgical Oncology

Einloggen, um Zugang zu erhalten

Abstract

Background

The size and importance of socioeconomic status (SES)-based disparities in use of surgery for non-advanced stage gastrointestinal (GI) cancers have not been quantified.

Methods

The exposure in this study of patients age 18–80 with one of nine non-advanced stage GI cancers in the 2007–2015 SEER database was a census tract-level SES composite. Multivariable models assessed associations of SES with use of surgery. Causal mediation analysis was used to estimate the proportion of survival disparities in SES quintiles 1 versus 5 that were mediated by disparities in use of surgery.

Results

Lowest SES quintile patients underwent surgery at significantly lower rates than highest quintile patients in each cancer. SES-based disparities in use of surgery were large and graded in esophagus adenocarcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma. Smaller but clinically relevant disparities were present in stomach, ampulla, and small bowel adenocarcinoma, whereas disparities were small in colorectal adenocarcinoma. Five-year all-stage overall survival (OS) was correlated with the size of disparities in use of surgery in SES quintiles 1 versus 5 (r = − 0.87; p = 0.003). Mean OS was significantly longer (range 3.5–8.9 months) in SES quintile 5 versus 1. Approximately one third of SES-based survival disparities in poor prognosis GI cancers were mediated by disparities in use of surgery. The size of disparities in use of surgery in SES quintiles 1 versus 5 was correlated with the proportion mediated (r = 0.98; p < 0.001).

Conclusions

Low SES patients with poor prognosis GI cancers are at substantial risk of undertreatment. Disparities in use of surgery contribute to diminished survival.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef
2.
Zurück zum Zitat Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950–2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.CrossRef Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950–2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.CrossRef
3.
Zurück zum Zitat McGhan LJ, Etzioni DA, Gray RJ, Pockaj BA, Coan KE, Wasif N. Underuse of curative surgery for early stage upper gastrointestinal cancers in the United States. J Surg Res. 2012;177(1):55–62.CrossRef McGhan LJ, Etzioni DA, Gray RJ, Pockaj BA, Coan KE, Wasif N. Underuse of curative surgery for early stage upper gastrointestinal cancers in the United States. J Surg Res. 2012;177(1):55–62.CrossRef
4.
Zurück zum Zitat Shapiro M, Chen Q, Huang Q, et al. Associations of socioeconomic variables with resection, stage, and survival in patients with early-stage pancreatic cancer. JAMA Surg. 2016;151(4):338–45.CrossRef Shapiro M, Chen Q, Huang Q, et al. Associations of socioeconomic variables with resection, stage, and survival in patients with early-stage pancreatic cancer. JAMA Surg. 2016;151(4):338–45.CrossRef
5.
Zurück zum Zitat Michalski CW, Liu B, Heckler M, et al. Underutilization of surgery in periampullary cancer treatment. J Gastrointest Surg. 2019;23(5):959–65.CrossRef Michalski CW, Liu B, Heckler M, et al. Underutilization of surgery in periampullary cancer treatment. J Gastrointest Surg. 2019;23(5):959–65.CrossRef
6.
Zurück zum Zitat Boswort B. Increasing disparities in mortality by socioeconomic status. Annu Rev Public Health. 2018;39:237–51.CrossRef Boswort B. Increasing disparities in mortality by socioeconomic status. Annu Rev Public Health. 2018;39:237–51.CrossRef
7.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80.CrossRef Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80.CrossRef
8.
Zurück zum Zitat Frohman HA, Martin JT, Le AT, Dineen SP, Tzeng CD. Failure to operate on resectable gastric cancer: implications for policy changes and regionalization. J Surg Res. 2017;214:229–39.CrossRef Frohman HA, Martin JT, Le AT, Dineen SP, Tzeng CD. Failure to operate on resectable gastric cancer: implications for policy changes and regionalization. J Surg Res. 2017;214:229–39.CrossRef
9.
Zurück zum Zitat Liu N, Molena D, Stem M, Blackford AL, Sewell DB, Lidor AO. Underutilization of treatment for regional gastric cancer among the elderly in the USA. J Gastrointest Surg. 2018;22(6):955–63.CrossRef Liu N, Molena D, Stem M, Blackford AL, Sewell DB, Lidor AO. Underutilization of treatment for regional gastric cancer among the elderly in the USA. J Gastrointest Surg. 2018;22(6):955–63.CrossRef
10.
Zurück zum Zitat Swords DS, Mulvihill SJ, Skarda DE, et al. Hospital-level variation in utilization of surgery for clinical stage I–II pancreatic adenocarcinoma. Ann Surg. 2019;269(1):133–42.CrossRef Swords DS, Mulvihill SJ, Skarda DE, et al. Hospital-level variation in utilization of surgery for clinical stage I–II pancreatic adenocarcinoma. Ann Surg. 2019;269(1):133–42.CrossRef
11.
Zurück zum Zitat Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Surgery. 2019;165(4):751–9.CrossRef Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Surgery. 2019;165(4):751–9.CrossRef
14.
Zurück zum Zitat Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v51–5.CrossRef Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v51–5.CrossRef
15.
Zurück zum Zitat Taylor LJ, Greenberg CC, Lidor AO, Leverson GE, Maloney JD, Macke RA. Utilization of surgical treatment for local and locoregional esophageal cancer: analysis of the National Cancer Data Base. Cancer. 2017;123(3):410–9.CrossRef Taylor LJ, Greenberg CC, Lidor AO, Leverson GE, Maloney JD, Macke RA. Utilization of surgical treatment for local and locoregional esophageal cancer: analysis of the National Cancer Data Base. Cancer. 2017;123(3):410–9.CrossRef
16.
Zurück zum Zitat Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2014;25(1):81–92.CrossRef Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2014;25(1):81–92.CrossRef
17.
Zurück zum Zitat Liu L, Deapen D, Bernstein L. Socioeconomic status and cancers of the female breast and reproductive organs: a comparison across racial/ethnic populations in Los Angeles County, California (United States). Cancer Causes Control. 1998;9(4):369–80.CrossRef Liu L, Deapen D, Bernstein L. Socioeconomic status and cancers of the female breast and reproductive organs: a comparison across racial/ethnic populations in Los Angeles County, California (United States). Cancer Causes Control. 1998;9(4):369–80.CrossRef
18.
Zurück zum Zitat Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for di. Cancer Causes Control. 2001;12(8):703–11.CrossRef Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for di. Cancer Causes Control. 2001;12(8):703–11.CrossRef
20.
Zurück zum Zitat Schisterman EF, Cole SR, Platt RW. Over adjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–95.CrossRef Schisterman EF, Cole SR, Platt RW. Over adjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–95.CrossRef
21.
Zurück zum Zitat Sauer BC, Brookhart A, Roy J, Vanderweele T. A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(11):1139–45.CrossRef Sauer BC, Brookhart A, Roy J, Vanderweele T. A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(11):1139–45.CrossRef
22.
Zurück zum Zitat Norton EC, Dowd BE, Maciejewski ML. Odds ratios—current best practice and use. JAMA. 2018;320(1):84–5.CrossRef Norton EC, Dowd BE, Maciejewski ML. Odds ratios—current best practice and use. JAMA. 2018;320(1):84–5.CrossRef
23.
Zurück zum Zitat Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata J. 2013;13(3):492–509.CrossRef Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata J. 2013;13(3):492–509.CrossRef
24.
Zurück zum Zitat Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380–5.CrossRef Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380–5.CrossRef
25.
Zurück zum Zitat Baugh KA, Tran Cao HS, van Buren G 2nd, et al. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Surgery. 2019;165(2):307–14.CrossRef Baugh KA, Tran Cao HS, van Buren G 2nd, et al. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Surgery. 2019;165(2):307–14.CrossRef
26.
Zurück zum Zitat Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery. 2017;162(1):104–11.CrossRef Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery. 2017;162(1):104–11.CrossRef
27.
Zurück zum Zitat VanderWeele TJ. Policy-relevant proportions for direct effects. Epidemiology. 2013;24(1):175–6.CrossRef VanderWeele TJ. Policy-relevant proportions for direct effects. Epidemiology. 2013;24(1):175–6.CrossRef
28.
Zurück zum Zitat VanderWeele TJ. A unification of mediation and interaction: a 4-way decomposition. Epidemiology. 2014;25(5):749–61.CrossRef VanderWeele TJ. A unification of mediation and interaction: a 4-way decomposition. Epidemiology. 2014;25(5):749–61.CrossRef
30.
Zurück zum Zitat Lufti W, Zenati M, Zureikat A, Zeh H, Hogg M. Health disparities impact expected treatment of pancreatic ductal adenocarcinoma nationally. Ann Surg Oncol. 2018;25(7)1860–7.CrossRef Lufti W, Zenati M, Zureikat A, Zeh H, Hogg M. Health disparities impact expected treatment of pancreatic ductal adenocarcinoma nationally. Ann Surg Oncol. 2018;25(7)1860–7.CrossRef
31.
Zurück zum Zitat McDowell BD, Chapman CG, Smith B.J., Button A.M., Chrischilles EA, Mezhir JJ. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg. 2015;261(4):740–5.CrossRef McDowell BD, Chapman CG, Smith B.J., Button A.M., Chrischilles EA, Mezhir JJ. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg. 2015;261(4):740–5.CrossRef
33.
Zurück zum Zitat Sridhar P, Misir P, Kwak H, et al. Impact of race, insurance status, and primary language on the presentation, treatment, and outcomes of patients with pancreatic adenocarcinoma at a safety-net hospital. J Am Coll Surg. 2019;229(4):389–96.CrossRef Sridhar P, Misir P, Kwak H, et al. Impact of race, insurance status, and primary language on the presentation, treatment, and outcomes of patients with pancreatic adenocarcinoma at a safety-net hospital. J Am Coll Surg. 2019;229(4):389–96.CrossRef
Metadaten
Titel
Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers
verfasst von
Douglas S. Swords, MD, MS
Sean J. Mulvihill, MD
Benjamin S. Brooke, MD, PhD
Matthew A. Firpo, PhD
Courtney L. Scaife, MD
Publikationsdatum
11.10.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07922-7

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.